Clinical Trials on Acquired Immunodeficiency Syndrome in Canada

Total 2111 results

Janssen Inc.

Completed

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

Human Immunodeficiency Virus (HIV)

Canada
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
McGill University Health Centre/Research Institute...
Université de Montréal; Argos Therapeutics

Completed

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.

Acquired Immunodeficiency Syndrome | HIV Seropositivity

Canada
Unity Health Toronto
Gilead Sciences; Ryerson University; Maple Leaf Research; AIDS Committee of Toronto and other collaborators

Completed

PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 (PREP-5)

HIV | Human Immunodeficiency Virus

Canada
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
Unity Health Toronto

Completed

Fetal HIV Transmission Risk and Duration of Membrane Rupture

HIV | Human Immunodeficiency Virus

Canada
Ottawa Heart Institute Research Corporation
Ontario HIV Treatment Network

Completed

The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients

Human Immunodeficiency Virus (HIV) | Cardiovascular Disease (CVD)

Canada
Marie-Josée Brouillette
Fonds de la Recherche en Santé du Québec; CIHR Canadian HIV Trials Network

Terminated

COMO: Cognition Study With HIV+ Patients (CTNPT 015) (COMO)

HIV - Human Immunodeficiency Virus | Cognitive Symptoms

Canada
Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
McGill University
Posit Science Corporation

Completed

Cognitive Training for the Remediation of Functional Brain Health in HIV

Cognitive Impairment | HIV - Human Immunodeficiency Virus

Canada
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Infections, Human Immunodeficiency Virus and Hepatitis

Canada
Canadian Immunodeficiency Research Collaborative

Completed

Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression

Human Immunodeficiency Virus

Canada
University of British Columbia
Simon Fraser University

Recruiting

The Positively Dance Pilot Program for Women Living With HIV (Dance)

Human Immunodeficiency Virus

Canada
EMD Serono

Completed

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

United States, Canada
McGill University Health Centre/Research Institute...
EMD Serono

Active, not recruiting

Impact of Recombinant Human Growth Hormone on HIV Persistence

Human Immunodeficiency Virus | Growth Hormone Treatment

Canada
Canadian Immunodeficiency Research Collaborative
Roche Pharma AG

Completed

Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration

Human Immunodeficiency Virus

Canada
GlaxoSmithKline

Completed

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
Gilead Sciences

Recruiting

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, South Africa, Argentina, Panama, Zimbabwe, United Kingdom, Uganda
The Hospital for Sick Children
Unity Health Toronto; Children's Hospital of Eastern Ontario; Mount Sinai Hospital... and other collaborators

Completed

Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection

HIV | Human Immunodeficiency Virus | Vertical Infection Transmission

Canada
McGill University
Sleepio

Terminated

A Sleep Program to Improve Sleep Quality in People With HIV

Insomnia Disorder | HIV - Human Immunodeficiency Virus

Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Unity Health Toronto

Unknown

Decision Support Intervention Adapted for HIV Pre-Exposure Prophylaxis for Adoption and Adherence for Black Canadians (PrEPDSA)

HIV/AIDS

Canada
Dr. Bertrand Lebouche
Canadian Institutes of Health Research (CIHR); Mitacs

Unknown

The I-Score Study: Developing a New Patient-Reported Tool for the Routine HIV Care of Patients on Antiretroviral Therapy

HIV/AIDS

Canada
Gilead Sciences

Completed

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

HIV Infections | Acquired Immunodeficiency Syndrome

Puerto Rico, United States, United Kingdom, Canada, Germany, Austria, Australia, Dominican Republic, Mexico
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
McGill University Health Centre/Research Institute...

Completed

Metformin Immunotherapy in HIV Infection

HIV Infection

Canada
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

Canada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

HIV Infection | HIV-1 | Human Immunodeficiency Virus (HIV)

United States, Australia, Canada, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

Human Immunodeficiency Virus - Type 1

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
Unity Health Toronto

Completed

HIV Testing in Pregnant Women: Evaluating an Opt-Out Testing Strategy

Pregnancy | HIV | AIDS Virus

Canada
ViiV Healthcare
Janssen Research and Development

Completed

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Human Immunodeficiency Virus Type 1 (HIV-1)

Germany, Spain, United States, Italy, Canada, Argentina, Sweden
ViiV Healthcare
GlaxoSmithKline

Completed

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I

United States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR); University of Toronto

Completed

Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? (VALIANT Pilot)

Herpes Simplex | Human Immunodeficiency Virus

Canada
ViiV Healthcare
GlaxoSmithKline

Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
Abbott
Merck Sharp & Dohme LLC

Completed

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) (PROGRESS)

Human Immunodeficiency Virus Infection

United States, Canada, France, Italy, Poland, Puerto Rico, Spain
ViiV Healthcare
GlaxoSmithKline

Completed

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Infection, Human Immunodeficiency Virus

United States, France, Spain, Canada, Italy
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (SONNET)

Infection, Human Immunodeficiency Virus

United States, Canada, Italy, Belgium, Romania
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
Unity Health Toronto

Unknown

Using Electronic Medical Record Data to Improve HIV Primary Care

HIV/AIDS | Electronic Health Records | Quality of Health Care

Canada
Ottawa Hospital Research Institute
CHEO Research Institute; Nebraska Centre for Substance Abuse Research

Recruiting

Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection (HAVARTI)

HIV-infection/AIDS

Canada
University of Toronto

Completed

Transgender Education for Affirmative and Competent HIV and Healthcare (TEACHH)

HIV/AIDS | Stigma, Social | Health Care Acceptability

Canada
BC Women's Hospital & Health Centre
Gilead Sciences

Completed

WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia (WelTelOAKTREE)

HIV | Medication Adherence

Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
Ottawa Hospital Research Institute
Octapharma

Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Primary Immunodeficiency Disease | Secondary Immunodeficiency

Canada
Ottawa Hospital Research Institute
Ontario HIV Treatment Network; CIHR Canadian HIV Trials Network

Completed

Micronutrients and Antioxidants in HIV Infection (MAINTAIN)

HIV Infection

Canada

Clinical Trials on Acquired Immunodeficiency Syndrome in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations